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Abstract
Ventilator-associated pneumonia, broadly defined as pneumonia that develops after 48 hours of
intubation, is a common mechanical ventilation complication that causes significant morbidity and
mortality in critically ill patients. Prevention strategies are continually evolving to decrease the impact
of this serious and costly disease.
Introduction and context
Ventilator-associated pneumonia (VAP) is thought to
develop from microorganisms entering the sterile lower
respiratory tract by aspiration of oropharyngeal secre-
tions containing bacteria endemic to the digestive tract or
exogenous pathogens acquired from contaminated
equipment or health care workers [1,2]. Less commonly,
the lower respiratory tract may be inoculated by direct
inhalation of pathogens, hematogenous spread from a
remote infection, or direct extension of a contiguous
infection [1,2]. The most common etiologic agents are
Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia
coli,Acinetobacter,and Staphylococcus aureus [1]. In healthy
hosts, mucociliary clearance and innate immunity
protect against pneumonia [2]. However, placement of
an endotracheal tube impairs mucociliary clearance and
provides a direct pathway for inoculation of the lower
respiratory tract while critical illness weakens the
immune system, putting critically ill, ventilated patients
at high risk for developing pneumonia [2].
Prevention strategies focus on decreasing bacterial
colonization of the oropharynx, reducing the frequency
of aspiration, maintaining the immune system, and
liberating patients from the ventilator as early as
possible. These strategies have improved over the past
decade and decreased the burden of disease. VAP
previously occurred in 9-18% of mechanically ventilated
patients [3] and was associated with a 20-50% mortality
rate and a 7- to 9-day increase in hospitalization [4].
Newer data suggest that VAP incidence is 2-10 per 1000
ventilator days [5]. The cost of diagnosing and treating
VAP is US $5,000 to $40,000 per incident [6,7]. Routine
prevention strategies are summarized in Table 1. Emer-
ging prevention strategies to consider in selected patient
populations are summarized in Table 2.
Recent advances
Decreasing bacterial colonization of the oropharynx
In 2005, the Infectious Diseases Society of America and
the American Thoracic Society published a comprehen-
sive guideline for VAP prevention focusing on modifi-
able risk factors [1]. In 2008, the Canadian Critical Care
Trials group published a similar guideline [8]. To
decrease bacterial colonization of the oropharynx and
endotracheal tube, these guidelines advocate using
orotracheal rather than nasotracheal intubation, contin-
uous subglottic secretion drainage, and standard infection
controlmeasures,includingfrequenthandwashing,sterile
central venous catheter placement, and isolation of
resistantorganisms.Whilecontinuoussubglotticsecretion
drainage requires a special endotracheal tube that costs
about US $12 more than a standard tube, several studies
have shown a significant reduction of VAP incidence with
this intervention, as summarized in a recent review [9].
Decontamination of the oropharynx and digestive tract
with systemic antibiotics, selective digestive decontamina-
tion, and selective oropharyngeal decontamination have
allbeenshowntodecreasebacterialcolonizationandVAP
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While many studies have demonstrated decreased VAP
incidence in patients treated with prophylactic antibiotics
[10], the guidelines recommend against their use until
more data on the effect on mortality and the risk of
developing resistant organisms emerge [1,8]. In 2009, De
Smet et al. [11] published the largest randomized trial to
date on selective gut decontamination. After baseline
differences between the treatment arms were adjusted for,
there was a significant decrease in mortality for those
treated with selective gut decontamination [11]. However,
concerns about the external validity of the study remain
because of the low incidence of resistant organisms
encountered in the study population [12].
Oralcleansingwithtopicalantisepticssuchaschlorhexidine
also reduces bacterial colonization with less potential for
selecting resistant organisms but is similarly controversial.
The 2005 guidelines recommend against using antiseptics
because of the paucity of data [1]. Many subsequent trials
on chlorhexidine have been published, but the results are
conflicting so the controversy persists. Several meta-
analyses [1,13] and clinical trials [14,15] suggest a benefit
of chlorehexidine in decreasing VAP, whereas others have
yielded negative results [16-18]. The 2008 guidelines
recommend that oral chlorhexidine be considered [8].
Since the 2008 guidelines were published, a new silver-
coated endotracheal tube designed to decrease bacterial
colonization and biofilm formation was introduced. The
NASCENT trial, a prospective, randomized, multi-center
study comparing standard and coated endotracheal
tubes, showed a significant reduction in VAP (4.8%
versus 7.5%, P = 0.03) in patients treated with this coated
tube. However, mechanical ventilation duration, hospi-
tal length of stay, and intensive care unit (ICU) length of
stay were unchanged between the control and interven-
tion groups [4]. A numeric increase in mortality among
patients assigned to the coated tubes (30.4% versus
26.6% for standard tubes, P =0 . 1 1 )n e e d st ob e
evaluated further [4]. Furthermore, the cost of a coated
tube is US $90 compared with $2 for a routine tube, but
a recent cost-effectiveness analysis concluded that silver-
coated tubes would likely save money because of their
ability to prevent VAP [19].
Decreasing the frequency of aspiration
Enteral nutrition predisposes patients to aspiration of
gastric contents and subsequent VAP [20] but is still
considered preferable to parenteral nutrition because of
the many complications associated with parenteral
nutrition [20,21]. The 2005 guidelines recommend
post-pyloric feeding tubes and semi-recumbent position-
ing with a head of bed angle of greater than 45 degrees to
decrease the frequency of aspiration associated with
enteral feeding [1]. Unfortunately, it is difficult to
maintain patients at 45 degrees, and 30 degree elevation
may not be as effective [22]. Some research suggests
that postponing full-calorie nutrition may be another
option [23]. A 2002 single-center study evaluating initial
trophic feeding followed by delayed full-calorie nutrition
found a significant reduction in VAP with no change
in mortality compared with the control group [23].
A multicenter trial is now under way to confirm these
results [24].
Maintaining natural immunity
Stress ulcer prophylaxis with acid suppression predis-
poses patients to developing VAP by raising the gastric
pH levels and allowing bacterial overgrowth [25].
Sucralfate is an appealing option because it does not
affectgastricpH,butithasbeenassociatedwithincreased
bleeding and VAP incidence [26,27]. Citing conflicting
evidence, the 2005 guidelines recommend using either
sucralfate or H2 blockers for stress ulcer prophylaxis [1].
More recently, acid suppression therapy with more
potent proton pump inhibitors has become widespread
[25], but it was associated with a greater incidence of VAP
than H2 blockers in a retrospective study [25]. To help
maintain natural immunity, the guidelines also recom-
mend a conservative transfusion policy and intensive
insulin therapy since blood transfusion and hyperglyce-
mia have been associated with increased infectious
complications [1]. However, intensive insulin regimens
have beenincreasinglyscrutinized as new datasuggesting
their potential for harm emerge [28-30].
Liberating patients from the ventilator
The 2005 guidelines recommend avoiding intubation,
and particularly reintubation whenever possible, as well
Table 1. Recommended prevention strategies for ventilator-
associated pneumonia in adult intensive care units
Avoidance of intubation and reintubation if possible
Orotracheal intubation over nasotracheal intubation
Continuous aspiration of subglottic secretions
Semi-recumbent positioning (head of bed elevated
30-45 degrees when possible)
Enteral feeding with post-pyloric feeding tube
Standard infection control measures
Daily sedation interruption paired with ventilator weaning protocol
Conservative transfusion policy
Sucralfate or H2 blockers over proton pump inhibitors for stress
ulcer prophylaxis
Table 2. Ventilator-associated pneumonia prevention strategies
to consider in selected patients
Early tracheostomy
Chlorhexidine mouthwash
Coated endotracheal tubes
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ventilator weaning [1]. In 2008, the Awakening and
Breathing Controlled trial confirmed the importance of
combining sedation and ventilator weaning protocols by
showing a shorter duration of mechanical ventilation
and significant mortality improvement in the interven-
tion group [31].
For patients who are unlikely to be liberated from the
ventilator quickly, early tracheostomy has been used to
mitigate the risks associated with endotracheal intuba-
tion, but its role is controversial. A 2004 randomized
clinical trial showed a significant reduction in VAP,
duration of mechanical ventilation, and mortality in
patients who received tracheostomy on ventilator day 2
rather than prolonged endotracheal intubation with
tracheostomy on ventilator day 14 [32]. However,
follow-up studies have not replicated these findings
[33,34]. A 2006 meta-analysis showed decreased ventila-
tion duration and ICU length of stay but no difference in
mortality or VAP in those treated with early tracheo-
stomy [34]. In 2008, a small randomized trial also
showed no difference between tracheostomy within the
first 4 days of intubation and prolonged intubation with
tracheostomy allowed only after ventilator day 14, other
than improved patient comfort, but the study was too
underpowered to be conclusive [33].
Implications for clinical practice
VAP leads to excess morbidity, mortality, and costs in
criticallyillpatients.Whilemanypreventionstrategieshave
proven successful in decreasing the incidence of VAP by a
small amount, significant reduction requires a multimodal
approach encompassing positioning, equipment, nutri-
tional support, infection control, sedation minimization,
and ventilator weaning. Adjunctive therapies such as stress
ulcer prophylaxis, glycemic control, and blood transfusion
also play a role because of their impact on the immune
system.Vigilantattentiontoallofthesedetailsbymeansof
a ventilator bundle has been shown to significantly reduce
the incidence of VAP [35,36]. Many other promising
therapies, such as selective gut decontamination, early
tracheostomy, and coated endotracheal tubes, remain
controversial because of their mixed or limited data, so
we await further trials to determine their role. VAP
prevention remains an area of active research, with 28
clinical trials currently listed on www.clinicaltrials.gov.
Abbreviations
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